BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/14/2025 12:55:56 PM | Browse: 195 | Download: 398
 |
Received |
|
2025-03-06 09:04 |
|
Peer-Review Started |
|
2025-03-06 09:04 |
|
First Decision by Editorial Office Director |
|
2025-03-26 11:19 |
|
Return for Revision |
|
2025-03-26 11:19 |
|
Revised |
|
2025-04-07 10:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-05-29 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-05-29 07:04 |
|
Articles in Press |
|
2025-05-29 07:04 |
|
Edit the Manuscript by Language Editor |
|
2025-06-04 19:06 |
|
Typeset the Manuscript |
|
2025-06-30 01:59 |
|
Publish the Manuscript Online |
|
2025-07-14 12:55 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Minireviews |
| Article Title |
Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Meng-Yan Chen, Chen Wang, Yu-Gang Wang and Min Shi |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of the Science and Technology Commission of Shanghai Municipality, China |
No. 23ZR1458300 |
| Key Discipline Project of Shanghai Municipal Health System, China |
No. 2024ZDXK0004 |
| Doctoral Innovation Talent Base Project for Diagnosis and Treatment of Chronic Liver Diseases, China |
No. RCJD2021B02 |
| Pujiang Project of Shanghai Magnolia Talent Plan, China |
No. 24PJD098 |
|
| Corresponding Author |
Min Shi, Chief Physician, MD, Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Changning District, Shanghai 200336, China. sm1790@shtrhospital.com |
| Key Words |
Colorectal cancer; Adoptive cell therapy; Immunotherapy; Chimeric antigen receptor T cells; Tumor-infiltrating lymphocytes; T-cell receptor-engineered T cells |
| Core Tip |
This review discusses adoptive cell therapy approaches for colorectal cancer (CRC), emphasizing chimeric antigen receptor (CAR) T cell therapy. Despite its success in hematological malignancies, CAR-T therapy faces challenges in solid tumors like CRC, including antigen heterogeneity, tumor microenvironment immunosuppression, and on-target off-tumor toxicity. The review explores combinatorial strategies, such as immune checkpoint inhibitors and clustered regularly interspaced short palindromic repeats/Cas9 gene editing, to overcome these challenges and enhance CAR-T cell specificity, resistance to immunosuppressive signals, and in vivo functionality. |
| Publish Date |
2025-07-14 12:55 |
| Citation |
Chen MY, Wang C, Wang YG, Shi M. Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells. World J Gastrointest Oncol 2025; 17(7): 106723 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i7/106723.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i7.106723 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
